Sign In
Buy QGEN
$37.56
+1.11 (+3.05%)
At Close: Jun 04, 2026
QIAGEN CEO details how company tracks the spread of COVID through wastewater testing
12:00am, Saturday, 11'th Jun 2022
This segment originally aired on June 6, 2022. QIAGEN CEO Thierry Bernard joins Yahoo Finance Live anchors Brian Cheung and Akiko Fujita to explain how his company is utilizing technology to track the
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Up 2.8% Since Last Earnings Report: Can It Continue?
03:30pm, Thursday, 09'th Jun 2022 Zacks Investment Research
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Novavax (NVAX) Down 11.7% Since Last Earnings Report?
03:30pm, Wednesday, 08'th Jun 2022 Zacks Investment Research
Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Fate Therapeutics (FATE) Down 14.1% Since Last Earnings Report?
03:31pm, Friday, 03'rd Jun 2022 Zacks Investment Research
Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain QIAGEN (QGEN) Stock for Now
01:46pm, Thursday, 19'th May 2022 Zacks Investment Research
Investors are optimistic about QIAGEN (QGEN), owing to strong international growth and bullish guidance.
QIAGEN (QGEN) Unveils New Enhancements to QIAstat-Dx Portfolio
04:49pm, Wednesday, 18'th May 2022 Zacks Investment Research
The launch of QIAstat-Dx Rise and other advancements to the QIAstat-Dx portfolio are expected to strengthen QIAGEN's (QGEN) syndromic testing solutions.
QIAGEN (QGEN) Unveils New Enhancements to QIAstat-Dx Portfolio
02:18pm, Wednesday, 18'th May 2022
The launch of QIAstat-Dx Rise and other advancements to the QIAstat-Dx portfolio are expected to strengthen QIAGEN's (QGEN) syndromic testing solutions.
QIAGEN (QGEN) to Acquire Poland-Based Enzymes Manufacturer
04:04pm, Monday, 16'th May 2022 Zacks Investment Research
The latest acquisition of BLIRT will allow QIAGEN (QGEN) to tap into the high opportunities within the life science industry.
QIAGEN (QGEN) to Acquire Poland-Based Enzymes Manufacturer
01:32pm, Monday, 16'th May 2022
The latest acquisition of BLIRT will allow QIAGEN (QGEN) to tap into the high opportunities within the life science industry.
Syneos Health (SYNH) Q1 Earnings Top Estimates, Margins Up
12:31pm, Monday, 02'nd May 2022 Zacks Investment Research
Syneos Health's (SYNH) revenues increased year over year in the first quarter, led by strong performances by the Clinical Solutions and Commercial Solutions arms.
Surmodics (SRDX) Beats on Q2 Earnings, Revises FY22 View
04:18pm, Friday, 29'th Apr 2022 Zacks Investment Research
Despite solid IVD revenues, Surmodics (SRDX) reports a soft Q2 overall top line.
Teleflex's (TFX) Q1 Earnings Top Estimates, Margins Down
03:02pm, Friday, 29'th Apr 2022 Zacks Investment Research
Teleflex (TFX) exhibits year-over-year growth across the Americas, EMEA and Asia regions at CER in the first quarter.
Accuray (ARAY) Q3 Earnings Beat Estimates, Revenues Lag
02:45pm, Friday, 29'th Apr 2022 Zacks Investment Research
Despite strong product demand, Accuray (ARAY) reports an overall soft Q3 performance.
Bio-Rad (BIO) Q1 Earnings Surpass Estimates, Margins Up
02:31pm, Friday, 29'th Apr 2022 Zacks Investment Research
Bio-Rad's (BIO) first-quarter 2022 revenues decline year over year due to lower COVID-related demand.
QIAGEN (QGEN) Q1 Earnings Surpass Estimates, 2022 View Up
02:30pm, Friday, 29'th Apr 2022 Zacks Investment Research
QIAGEN (QGEN) exited first-quarter 2022 with better-than-expected results on strength in the non-COVID product portfolio driving the top line.
